Furthermore, saxagliptin (one of dipeptidyl peptidase-4 inhibitors) was associated increased risk of heart failure admission in post-hoc analysis of SAVOR-TIMI 53 trial [33]. The gene discussed is DPP4; the disease is heart failure.